Free Trial
NASDAQ:CNSP

CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

CNS Pharmaceuticals logo
$1.01 +0.01 (+1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.04 +0.03 (+3.47%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CNS Pharmaceuticals Stock (NASDAQ:CNSP)

Key Stats

Today's Range
$0.96
$1.08
50-Day Range
$0.82
$1.36
52-Week Range
$0.77
$447.00
Volume
390,451 shs
Average Volume
683,323 shs
Market Capitalization
$5.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Moderate Buy

Company Overview

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

CNSP MarketRank™: 

CNS Pharmaceuticals scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CNS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    CNS Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about CNS Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CNS Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CNS Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about CNS Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.50% of the float of CNS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently increased by 16.16%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CNS Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    CNS Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.50% of the float of CNS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CNS Pharmaceuticals has recently increased by 16.16%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CNS Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.
  • Search Interest

    3 people have searched for CNSP on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.07% of the stock of CNS Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 14.02% of the stock of CNS Pharmaceuticals is held by institutions.

  • Read more about CNS Pharmaceuticals' insider trading history.
Receive CNSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNSP Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

CNSP Stock Analysis - Frequently Asked Questions

CNS Pharmaceuticals' stock was trading at $6.02 at the start of the year. Since then, CNSP shares have decreased by 83.2% and is now trading at $1.01.
View the best growth stocks for 2025 here
.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) posted its earnings results on Thursday, May, 15th. The company reported ($1.58) EPS for the quarter.

CNS Pharmaceuticals shares reverse split on the morning of Friday, February 21st 2025. The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

CNS Pharmaceuticals (CNSP) raised $9 million in an IPO on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO.

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE).

Company Calendar

Last Earnings
5/15/2025
Today
6/03/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CNSP
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+2,451.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.85 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($35.66) per share
Price / Book
-0.03

Miscellaneous

Free Float
57,447,000
Market Cap
$5.35 million
Optionable
Not Optionable
Beta
2.67
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CNSP) was last updated on 6/3/2025 by MarketBeat.com Staff
From Our Partners